Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1700793 | 1.00 | GAA (0.49) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL10627733 | 0.82 | GAA (0.41) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL10627727 | 0.82 | GAA (0.41) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL1619527 | 0.81 | GAA (0.55) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL935624 | 0.81 | GAA (0.55) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL29180233 | 0.78 | CYP3A4 (0.33) | GAALMNATSHRPOLBCYP3A4 | |
| SCHEMBL80480 | 0.78 | LMNA (0.58) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL815103 | 0.78 | LMNA (0.58) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL4110354 | 0.78 | GAA (0.43) | GAALMNATSHRPOLBCNR1 | |
| SCHEMBL905284 | 0.78 | LMNA (0.58) | GAALMNATSHRPOLBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56126440-A | — | — | None | — | — | JP | disclosed |
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | DRACEN PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2020150639-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | DRACEN PHARMACEUTICALS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-2566335-B1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2016-06-29 | — | — | EP | disclosed |
| CN-103025165-B | From the controlled release of macromolecular conjugates | 普罗林科斯有限责任公司 | 2016-06-08 | — | — | CN | disclosed |
| US-8754190-B2 | Controlled release from macromolecular conjugates | PROLYNX LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC | 2013-05-09 | — | — | US | disclosed |
| CN-103025165-A | Controlled release from macromolecular conjugates | PROLYNX LLC | 2013-04-03 | — | — | CN | disclosed |
| EP-2566335-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | Prolynx Llc (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140393-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | PROLYNX LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| EP-0342055-B1 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1994-01-12 | — | — | EP | disclosed |
| EP-0342054-B1 | Cosmetic composition | UNILEVER PLC (GB) | 1993-11-03 | — | — | EP | disclosed |
| EP-0342055-A2 | Use of pyroglutamic acid alkyl esters for the manufacture of a medicament for the treatment of ichthyosis | UNILEVER PLC (GB) | 1989-11-15 | — | — | EP | disclosed |
| JP-S56126440-A | EMULSIFICATION STABILIZING ASSISTANT | AJINOMOTO CO INC | 1981-10-03 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246902-A1 | PRODRUGS OF 6-DIAZO-5-OXO-L-NORLEUCINE | GLUL, GLS, GLS2 | GAA 46/4885LMNA 4370/4885TSHR 3570/4885 |
| US-20220117938-A1 | COMBINATON THERAPY WITH A DON PRODRUG AND AN IMMUNE CHECKPOINT INHIBITOR | PDCD1, CD274, BID | GAA 2949/4885LMNA 4061/4885TSHR 1822/4885 |
| US-20130116407-A1 | CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES | ABCB1, ABCB11, GUSB | GAA 80/4885LMNA 2174/4885TSHR 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.